Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02492711
Title Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors MacroGenics
Indications

Her2-receptor positive breast cancer

Therapies

Vinorelbine

Capecitabine

Gemcitabine

Trastuzumab

Eribulin

Margetuximab-cmkb

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.